Thierry Jahan
About
Thierry Jahan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Thierry Jahan has authored 79 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Thierry Jahan's work include Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Occupational and environmental lung diseases (13 papers). Thierry Jahan is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Occupational and environmental lung diseases (13 papers). Thierry Jahan collaborates with scholars based in United States, United Kingdom and France. Thierry Jahan's co-authors include David M. Jablons, Janine K. Cataldo, Christine Miaskowski, Bradley E. Aouizerat, Hedy L. Kindler, Marylin J. Dodd, Raffit Hassan, Anish Thomas, Won Ju Hwang and Robert Slaughter and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.
In The Last Decade
Thierry Jahan
76 papers receiving 3.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thierry Jahan United States | 28 | 1.8k | 1.8k | 680 | 327 | 290 | 79 | 3.5k | ||
| Tracey L. Evans United States | 29 | 2.1k 1.2× | 2.1k 1.2× | 933 1.4× | 509 1.6× | 583 2.0× | 107 | 4.0k | ||
| Jason A. Wampfler United States | 28 | 1.8k 1.0× | 1.7k 1.0× | 586 0.9× | 140 0.4× | 350 1.2× | 65 | 3.0k | ||
| Ganessan Kichenadasse Australia | 30 | 1.1k 0.6× | 1.9k 1.1× | 612 0.9× | 222 0.7× | 385 1.3× | 168 | 3.4k | ||
| Alan P. Lyss United States | 27 | 879 0.5× | 1.2k 0.7× | 374 0.6× | 274 0.8× | 327 1.1× | 66 | 2.7k | ||
| Laura Giordano Italy | 31 | 873 0.5× | 982 0.6× | 387 0.6× | 318 1.0× | 230 0.8× | 165 | 3.3k | ||
| Giannis Mountzios Greece | 30 | 971 0.5× | 1.6k 0.9× | 1.0k 1.5× | 156 0.5× | 507 1.7× | 124 | 3.2k | ||
| Susanne M. Arnold United States | 28 | 767 0.4× | 1.1k 0.6× | 791 1.2× | 289 0.9× | 353 1.2× | 166 | 2.8k | ||
| Sara Pilotto Italy | 29 | 1.1k 0.6× | 1.8k 1.0× | 813 1.2× | 324 1.0× | 485 1.7× | 187 | 2.9k | ||
| James D. Bearden United States | 31 | 888 0.5× | 1.7k 0.9× | 304 0.4× | 252 0.8× | 265 0.9× | 94 | 3.1k | ||
| Steve Scoppa United States | 11 | 827 0.5× | 1.7k 1.0× | 803 1.2× | 386 1.2× | 515 1.8× | 17 | 3.7k |
Countries citing papers authored by Thierry Jahan
Since
Specialization
Citations
This map shows the geographic impact of Thierry Jahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Jahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Jahan more than expected).
Fields of papers citing papers by Thierry Jahan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thierry Jahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Jahan. The network helps show where Thierry Jahan may publish in the future.
Co-authorship network of co-authors of Thierry Jahan
This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Jahan. A scholar is included among the top collaborators of Thierry Jahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Jahan. Thierry Jahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Baas, Paul, Arnaud Scherpereel, Anna K. Nowak, et al.. (2020). ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. Journal of Thoracic Oncology. 15(10). e42–e42.
2.
Hassan, Raffit, Evan Alley, Hedy L. Kindler, et al.. (2019). Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research. 25(19). 5787–5798.
3.
Rotow, Julia, Anatoly Urisman, Caroline E. McCoach, et al.. (2019). P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S578–S578.
4.
Kratz, Johannes R., Nancy R. Cook, Jianxing He, et al.. (2019). Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging. Journal of Thoracic Oncology. 14(7). 1223–1232.
5.
Kindler, Hedy L., Nofisat Ismaila, Samuel G. Armato, et al.. (2018). Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 36(13). 1343–1373.
6.
Utne, Inger, Borghild Løyland, Ellen Karine Grov, et al.. (2018). Distinct attentional function profiles in older adults receiving cancer chemotherapy. European Journal of Oncology Nursing. 36. 32–39.
7.
Daigle, Scott R., Silvia Stacchiotti, Patrick Schöffski, et al.. (2018). Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). Annals of Oncology. 29. viii670–viii670.
8.
Aggarwal, Rahul, Scott Thomas, Nela Pawłowska, et al.. (2017). Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. Journal of Clinical Oncology. 35(11). 1231–1239.
9.
Jahan, Thierry, Raffit Hassan, Evan Alley, et al.. (2016). 208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial. Journal of Thoracic Oncology. 11(4). S156–S156.
10.
Hassan, Raffit, Hedy L. Kindler, Thierry Jahan, et al.. (2014). Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. Clinical Cancer Research. 20(23). 5927–5936.
11.
Jablons, David M., et al.. (2013). Divergent Management Strategies for Typical Versus Atypical Carcinoid Tumors of the Thoracic Cavity. American Journal of Clinical Oncology. 37(4). 350–355.
12.
Clément-Duchêne, Christelle, Ronald B. Natale, Thierry Jahan, et al.. (2012). A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 78(1). 57–62.
13.
Weinberg, Vivian, et al.. (2011). Implications of Delayed Initiation of Radiotherapy: Accelerated Repopulation after Induction Chemotherapy for Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(11). 1857–1864.
14.
Gilbertson‐White, Stephanie, Bradley E. Aouizerat, Thierry Jahan, & Christine Miaskowski. (2011). A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer. Palliative & Supportive Care. 9(1). 81–102.
15.
Kim, Esther, Thierry Jahan, Bradley E. Aouizerat, et al.. (2009). Changes in symptom clusters in patients undergoing radiation therapy. Supportive Care in Cancer. 17(11). 1383–1391.
16.
Rivera, M. Patricia, Frank C. Detterbeck, Mark A. Socinski, et al.. (2009). Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal. 135(6). 1588–1595.
17.
Detterbeck, Frank C., Mark A. Socinski, Richard J. Gralla, et al.. (2008). Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(1). 37–45.
18.
Nemunaitis, John, Thierry Jahan, Helen J. Ross, et al.. (2006). Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Therapy. 13(6). 555–562.
19.
Shu, Hui‐Kuo G., Thierry Jahan, Mack Roach, et al.. (2002). Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery. 124(6). 1183–1189.
20.
Venook, Alan P., Merrill J. Egorin, Guy Rosner, et al.. (1998). Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.. Journal of Clinical Oncology. 16(5). 1811–1819.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tracey L. Evans Breakdown of academic impact, for papers by Jason A. Wampfler Breakdown of academic impact, for papers by Ganessan Kichenadasse Breakdown of academic impact, for papers by Alan P. Lyss Breakdown of academic impact, for papers by Laura Giordano Breakdown of academic impact, for papers by Giannis Mountzios Breakdown of academic impact, for papers by Susanne M. Arnold Breakdown of academic impact, for papers by Sara Pilotto Breakdown of academic impact, for papers by James D. Bearden Breakdown of academic impact, for papers by Steve Scoppa